We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aquinox Pharmaceuticals Inc | NASDAQ:AQXP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.68 | 3.35 | 3.80 | 0 | 01:00:00 |
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐
Check the appropriate box:
☐ |
Preliminary Proxy Statement |
|
☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) | |
☐ |
Definitive Proxy Statement |
|
☒ |
Definitive Additional Materials |
|
☐ |
Soliciting Material Pursuant to § 240.14a-12 |
Neoleukin Therapeutics, Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box)
☒ |
No fee required. |
|||
☐ |
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|||
1. |
Title of each class of securities to which transaction applies:
|
|||
2. |
Aggregate number of securities to which transaction applies:
|
|||
3. |
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
|
|||
4. |
Proposed maximum aggregate value of transaction:
|
|||
5. |
Total fee paid:
|
|||
☐ |
Fee paid previously with preliminary materials. |
|||
☐ |
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
|||
6. |
Amount Previously Paid:
|
|||
7. |
Form, Schedule or Registration Statement No.:
|
|||
8. |
Filing Party:
|
|||
9. |
Date Filed:
|
*** Exercise Your Right to Vote ***
Important Notice Regarding the Availability of Proxy Materials for the
Stockholder Meeting to Be Held on November 12, 2019.
NEOLEUKIN THERAPEUTICS, INC. |
Meeting Information |
|||||||
Meeting Type: Annual Meeting |
||||||||
For holders as of: September 18, 2019 |
||||||||
Date: November 12, 2019 Time: 1:30 p.m. local time |
||||||||
Location: |
Fenwick & West LLP |
|||||||
1191 2nd Avenue |
||||||||
FI. 10 Seattle, Washington 98101
|
||||||||
|
NEOLEUKIN THERAPEUTICS, INC. C/O PROXY SERVICES P.O. BOX 9142 FARMINGDALE, NY 11735 |
You are receiving this communication because you hold shares in the company named above.
This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).
We encourage you to access and review all of the important information contained in the proxy materials before voting.
|
||||||
See the reverse side of this notice to obtain proxy materials and voting instructions. |
||||||||
Before You Vote
How to Access the Proxy Materials
Voting Items |
The Board of Directors recommends you vote FOR the following: |
||||||||||||
1. |
Election of Directors |
|||||||||||
Nominees: |
||||||||||||
01) |
Jonathan G. Drachman |
|
|
|||||||||
02) |
Sarah B. Noonberg |
|||||||||||
The Board of Directors recommends you vote FOR the following proposals: |
||||||||||||
2. |
To approve the conversion of 101,927 shares of the companys non-voting convertible preferred stock issued to the former equity holders of Neoleukin Therapeutics, Inc. (Former Neoleukin) in connection with the completed acquisition of Former Neoleukin, into 10,192,700 shares of the companys common stock. |
|||||||||||
3. |
To approve an amendment to the companys Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 100,000,000. |
|||||||||||
4. |
To approve, at the discretion of the Board of Directors, an amendment to the companys Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio not less than 1-for-2 and not greater than 1-for-5, with the exact ratio to be set within that range at the discretion of the Board of Directors before December 31, 2020, and a corresponding reduction in the number of authorized shares of common stock, without further approval or authorization of the stockholders. |
|||||||||||
5. |
To approve amendments to the companys 2014 Equity Incentive Plan to, among other things, increase the number of shares of the companys common stock available for grant and issuance thereunder by 4,500,000 shares. |
|||||||||||
6. |
To ratify the appointment of Deloitte LLP as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2019. |
|||||||||||
7. |
To approve one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve the Proposal Nos. 1 through 6 at the time of the Annual Meeting or in the absence of a quorum. |
|||||||||||
NOTE: In their discretion, the proxies are authorized to vote upon such business as may properly come before the meeting. |
||||||||||||
|
Voting Items |
The Board of Directors recommends you vote FOR the following: |
||||||||||||
1. |
Election of Directors |
|||||||||||
Nominees: |
||||||||||||
01) |
Jonathan G. Drachman |
|
|
|||||||||
02) |
Sarah B. Noonberg |
|||||||||||
The Board of Directors recommends you vote FOR the following proposals: |
||||||||||||
3. |
To approve an amendment to the companys Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 to 100,000,000. |
|||||||||||
4. |
To approve, at the discretion of the Board of Directors, an amendment to the companys Amended and Restated Certificate of Incorporation to effect a reverse stock split at a ratio not less than 1-for-2 and not greater than 1-for-5, with the exact ratio to be set within that range at the discretion of the Board of Directors before December 31, 2020, and a corresponding reduction in the number of authorized shares of common stock, without further approval or authorization of the stockholders. |
|||||||||||
5. |
To approve amendments to the companys 2014 Equity Incentive Plan to, among other things, increase the number of shares of the companys common stock available for grant and issuance thereunder by 4,500,000 shares. |
|||||||||||
6. |
To ratify the appointment of Deloitte LLP as the independent registered public accounting firm of the company for its fiscal year ending December 31, 2019. |
|||||||||||
7. |
To approve one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve the Proposal Nos. 1 through 6 at the time of the Annual Meeting or in the absence of a quorum. |
|||||||||||
NOTE: In their discretion, the proxies are authorized to vote upon such business as may properly come before the meeting. |
||||||||||||
|
1 Year Aquinox Pharmaceuticals Chart |
1 Month Aquinox Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions